---
layout: default
title: Arnica Montana Whole Artemisia Abrotanum Flowering
parent: 僅模型預測 (L5)
nav_order: 415
evidence_level: L5
indication_count: 0
---

# Arnica Montana Whole Artemisia Abrotanum Flowering
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# 多成分順勢療法複方: 無法完成老藥新用預測評估

## One-Sentence Summary

This product is a multi-ingredient homeopathic combination containing 11 botanical, animal, and mineral components (including Arnica montana, Gelsemium sempervirens, Nitroglycerin/Gloninum, and Selenicereus grandiflorus), whose profile is consistent with a classical homeopathic cardiovascular/neuralgic remedy.
The TxGNN model **could not generate any predicted indication** for this compound because no DrugBank ID was matched and no original approved indication was found.
There is currently **no clinical trial or published literature evidence** that can be attributed to this specific formulation.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | None on record (no approved license found) |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — model prediction only; in this case, not even a model prediction is available |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why No Prediction Was Generated

TxGNN relies on a drug node anchored to a **DrugBank ID** and at least one **approved indication** to traverse the knowledge graph and score disease candidates. This compound has neither:

1. **No DrugBank ID** — The query string is a semicolon-delimited list of 11 raw ingredient names. None resolved to a single DrugBank entity. Without a node in the knowledge graph, neither the KG-path method nor the deep-learning model can propagate scores.

2. **No original approved indication** — The Taiwan (US) regulatory database returned zero licenses. Without a source disease anchor, the "From X to Y" repurposing frame cannot be constructed.

3. **Homeopathic product complexity** — Multi-ingredient homeopathic preparations are generally not represented as single entities in standard pharmacological databases (DrugBank, ChEMBL). Each ingredient would need to be evaluated individually, and ultra-dilute homeopathic preparations lack the receptor-binding or pharmacokinetic data required by TxGNN.

Because all three preconditions for a TxGNN evaluation are absent, the pipeline correctly returned an empty `predicted_indications` array. This is not a data pipeline error — it is an expected and valid result for this class of product.

---

## US Market Information

No US NDA or approved license exists for this product.

| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---------------------|-------------|-------------|---------------------|
| — | — | — | No records found |

---

## Safety Considerations

No structured safety data (warnings, contraindications, or drug-drug interactions) was retrieved from any source queried on 2026-03-24. Please refer to individual ingredient monographs and any available package insert for safety information.

**Notable individual-ingredient flags for clinical awareness:**

- **Nitroglycerin** (Gloninum in homeopathic nomenclature): At pharmacological doses, nitroglycerin is a potent vasodilator with well-characterised interactions with PDE-5 inhibitors (e.g., sildenafil) and antihypertensives. Whether the ultra-dilute homeopathic preparation carries the same risk profile is not established.
- **Gelsemium sempervirens**: The mother tincture contains strychnine-related alkaloids (gelsemine); toxicity at crude doses is documented. Homeopathic dilutions are generally regarded as non-toxic, but this should be confirmed per labelling.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This product cannot be evaluated through the standard TxGNN repurposing pipeline because it lacks both a DrugBank node and an approved indication anchor. Proceeding without resolving these gaps would produce results with no scientific basis.

**To proceed, the following is needed:**

1. **Clarify the target compound** — Determine whether the intent is to evaluate a specific single active ingredient (e.g., nitroglycerin alone) or the combination product as a whole. If a single active, resubmit with that INN and its DrugBank ID.
2. **Obtain a DrugBank ID** — Map the intended active ingredient(s) to DrugBank entries so the TxGNN knowledge graph node can be identified.
3. **Confirm approved indication(s)** — Identify at least one jurisdiction where this product (or the primary active) holds an approved indication to serve as the repurposing "source" disease.
4. **Decide on homeopathic scope** — If the strategic interest is homeopathic product repurposing specifically, a separate evaluation framework outside TxGNN (e.g., systematic review of clinical evidence per individual ingredient) should be designed, as TxGNN is not validated for ultra-dilute preparations.
5. **Retrieve safety data** — Once the active ingredient is clarified, pull TFDA package insert, DrugBank warnings, and DDI database entries to complete the S1 safety screening.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

